Drug Profile


Alternative Names: TXA 127

Latest Information Update: 03 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tarix Orphan; Tarix Pharmaceuticals
  • Developer Constant Pharmaceuticals; Tarix Pharmaceuticals; Unigene Laboratories; US Biotest Inc
  • Class Antihypertensives; Heart failure therapies; Peptide hormones
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Muscular dystrophies; Duchenne muscular dystrophy; Myelodysplastic syndromes; Pulmonary arterial hypertension; Limb girdle muscular dystrophies; Stem cell engraftment
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Connective tissue disorders; Duchenne muscular dystrophy; Epidermolysis bullosa; Limb girdle muscular dystrophies; Muscular dystrophies; Stroke
  • Discontinued Adult respiratory distress syndrome; HIV infections; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Thrombocytopenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 27 Mar 2018 Constant Pharmaceuticals will receive patent allowance for Angiotensin-1-7 in the European Union
  • 27 Mar 2018 Constant Pharmaceuticals plans a phase II trial for stroke recovery in the early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top